By Dr.Asmaa Al sanjary

Size: px
Start display at page:

Download "By Dr.Asmaa Al sanjary"

Transcription

1 By Dr.Asmaa Al sanjary

2 Preterm delivery is defined by a birth occurring before 37 completed weeks of gestation. Prematurity is multifactorial and its incidence has increased during the last decade in most occidental countries, probably due to increased risk factors responsible for elective prematurity. The mechanisms for preterm labour are still unclear. It could be associated either with a premature activation of the physiological contracting process or with a pathological factor responsible for uterine contractions, leading to preterm delivery.

3 Tocolytic drugs have been available for several decades but their actions are directed toward the effects and not the causes of preterm labour. Tocolysis aims not only to inhibit uterine contractions but also to allow a safe transfer of the pregnant patient to a tertiary care centre,it gives the opportunity to administrate corticosteroids for preventing neonatal risks associated with prematurity Their efficacy depend on an early and accurate diagnosis of the condition; the fetal fibronectin, and cervical length ultrasonography.

4

5 Drugs safety and side effect profile is a major concern not only for the pregnant women but also for the fetus. administration route and the optimal range of gestational age for these treatments

6 Are utilized as a tocolytic since the 1970s. Ritodrine was the first tocolytic approved by the FDA in 1980; it was voluntarily removed from the market in 1993 due to concerns of serious adverse effects. Due to recent warnings from the FDA concerning the lack of safety with the prolonged use of terbutaline, its use as a preventative agent or use beyond 48 to 72 hours is no longer recommended. In addition, oral terbutaline is not recommended as its effectiveness has not been established

7 Common adverse effects, when beta-agonists are compared to no treatment or placebo, include palpitation(68% with beta-agonists vs. 5% with controls), Tremor (39% vs. 4%), nausea (20% vs. 12%), headache (23%vs. 6%) and chest pain (10% vs. 1%). Rare, but serious and potentially life threatening adverse effects have been reported following beta-agonists use and a few maternal deaths associated with the use of these drugs were reported.

8 Pulmonary edema is a well-documented Complication, usually associated with aggressive Intravenous hydration. A systematic review reported one case of pulmonary edema among 850 women (1/425 with beta-agonists vs. 0/427 with placebo).

9 In conclusion, despite their efficiency, β 2 agonists safety profile is a real concern responsible for therapy discontinuation and choosing alternative tocolytic drugs.

10 Other tocolytic drugs (magnesium sulphate, indomethacin and atosiban),has fewer types of adverse effects reported and these occurred Less frequently.

11 These agents are in competition with the myometrial and decidual oxytocin receptors. The only drug used in clinical practice is atosiban. It blocks in a reversive manner the intracytoplasmic calcium release associated with contractions and downregulates prostaglandin synthesis.

12 Atosiban is widely used in clinical practice because of its low side effects profile and seems to be an adequate therapeutic choice for Effective tocolysis with a low maternal and fetal adverse effects profile.

13 Atosiban represents an advance in currently available tocolytics, and should be considered a first-line tocolytic for the management of SPTL. Atosiban is licensed in Europe for treatment of SPTL. The recommended dosage and administration schedule for atosiban is a three-step procedure. Duration of treatment should not exceed 48 h and the total dose given during a full course should preferably not exceed 330 mg of atosiban. In the early gestational age with or without PPROM, the use of atosiban can be prolonged for a further few days without any significant side effects.

14 For atosiban, the only documented adverse effect is nausea (11% with atosiban vs.5% with placebo) but this is only of short duration and only in association within about a minute during which the bolus dose is administered.

15 As magnesium is a calcium antagonist, it decreases calcium intracellular concentration no benefit of Magnesium sulphate administration over placebo use in preterm labour. As the drug is crossing the placenta, there were concerns about fetal safety. An increased risk of perinatal death and neonatal neurological and metabolic adverse effects at high dosage. Higher risk of death but a non-significant reduction in cerebral palsy at 18-months (corrected age) in infants exposed to magnesium sulfate.

16 It can also affect maternal neuromuscular system. Over a serum concentration of 9 mg/dl, there is a high toxicity risk resulting in disappearance of reflexes and respiratory depression and at 18mg/dl there is risk of cardiac arrest. Despite questionable safety and efficacy, still be used by obstetrician as their primary tocolytic therapy.

17 There is no evidence any more to recommend this drug as a first-line tocolytic agent.

18 Prostaglandin-synthase or cyclooxygenase (COX) isoforms COX-1 and -2 are essential enzymes for converting arachidonic acid to prostaglandins. Indomethacin, a nonspecific COX inhibitor, has been reported in studies and in a recent metaanalysis to be an efficient tocolytic drug compared to placebo, significantly delaying preterm delivery. It can be administrated rectally or orally.

19 Its use should be restricted in duration as the drug use for 2 days will not cause oligohydraminos. It should be limited to pregnancies below 32 weeks because of fetal ductus arteriosus closure risk and decreased urine production responsible for oligohydramnios. These treatments also have maternal side effects including gastric ulcer or asthma recurrence. COX-2 inhibitors such as nimesulide or rofecoxib have been studied in animal but not yet in humans and are not actually recommended for preventing preterm labour in clinical practice. In conclusion, indomethacin is an efficient tocolytic drug with no serious adverse drug reaction and is indicated for short-term effect during the second trimester of pregnancy.

20 Calcium-Channel Blockers :These agents are interfering with the calcium ions transfer through the myometrial cell membrane. They decrease intracellular free calcium concentration and induce myometrial relaxation. Nifedipine is the most commonly used single drug for preterm labour inhibition. nifedipine compared with β adrenergic receptor agonists has higher efficiency and a lower side effects.

21 Nifidipine is used at a daily dose of mg daily. An initial loading dose of 20 mg orally is given orally, followed by mg every 6 8 hours. The sublingual form is not recommended for treatment of preterm labor because it acts more rapidly than the oral form and can cause acute hypotension.

22 Nifidipine is commonly used in clinical practice as they has being generally well-tolerated as a single agent therapy. Use with magnesium sulfate should be avoided as it has resulted in harmful consequences including cardiovascular collapse.

23 nifedipine is an efficient tocolytic agent, with an easy oral route of administration, few side effects, and a low neonatal complications rate. However, it should be used with caution in patients with compromised cardiovascular condition as they may be at risk of pulmonary oedema and cardiac failure

24 NO is a powerful vasodilator synthesized during an amino acid oxidation process catalysed by NO synthase. It is present in myometrial cells and increases cgmp content by interaction with guanylyl cyclase. Transdermal nitroglycerin administration has been used in preterm labour only in small series, It has better tocolytic effect than placebo on delaying delivery for two days(similar to ritodrine). Major side effects are maternal headache and sever hypotension. There is risk of tocolysis failure

25 there is no large randomized studies available, NO is not used in clinical routine. Its use still exparmental.

26 Some drugs are used as first-line single therapy such as β adrenergic receptor agonists and atosiban in Europe.while in America Atosiban is not licensed for use as it s believed not reduce the incidence of preterm birth or improve neonatal outcomes when compared to placebo,with increase in fetal/infant death seen in those exposed to atosiban.

27 severe cases, combined therapy could be offered but should be restricted because of adverse effects addition and no improvement in perinatal outcome. The combination of magnesium sulphate and nifedipine should be avoided because of reported cases of symptomatic hypocalcemia, Neuromuscular blockade, and cardiac toxicity, including maternal death.

28 calcium channel blockers, particularly nifedipine, are used as a reasonable choice for initial tocolysis due to the low incidence of adverse effects, oral route of administration, efficacy in improving neonatal outcomes, and potential for use at any gestational age. Indomethacin is an available alternative for pregnancies of less than 32 weeks gestation as Premature closure of the ductus arteriosus has been shown to occur more often in those >32 weeks, it should be avoided in patients at increased risk of bleeding and those with renal or hepatic insufficiency, gastrointestinal disease, or asthma.

29 Specific conditions are subject to discussion: in multiple pregnancies, expanded blood volume and anaemia may predispose to pulmonary oedema when tocolytic agents such as β adrenergic receptor agonists,magnesium sulphate, and calcium channel blockers are prescribed. In these pregnancies, atosiban, with its low side effects incidence, seems to be the safest choice.

30 Last generation of oxytocin receptor antagonists such as barusiban could be more efficient and have less affinity for the vasopressin receptors. Specific COX-2 inhibitors or coxibs, prostaglandin receptors antagonists could be promising tocolytic alternatives

31

Tocolytics. Tocolytics (terbutaline, magnesium sulfate injection) Description

Tocolytics. Tocolytics (terbutaline, magnesium sulfate injection) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.06 Subject: Tocolytics Page: 1 of 5 Last Review Date: September 15, 2016 Tocolytics Description Tocolytics

More information

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Acute and Maintenance Page 1 of 11 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Acute and Maintenance Subcutaneous and Intravenous Tocolysis Professional

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): December 8, 2003 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

Kofinas Perinatal Providing Care to the Unborn

Kofinas Perinatal Providing Care to the Unborn Alexander D. Kofinas, MD Director, Kofinas Perinatal Associate Professor, Clinical Obstetrics and Gynecology Cornell University, College of Medicine Patient instructions for the use of Indomethacin and

More information

Medical Policy. MP Acute and Maintenance Tocolysis

Medical Policy. MP Acute and Maintenance Tocolysis Medical Policy MP 5.01.07 BCBSA Ref. Policy: 5.01.07 Last Review: 08/30/2017 Effective Date: 08/30/2017 Section: Prescription Drugs End Date: 08/19/2018 Related Policies 4.01.16 Progesterone Therapy as

More information

Pre-term birth occurs when a neonate is birthed or

Pre-term birth occurs when a neonate is birthed or Susan L. Rideout, RN-C, BSN Pre-term birth occurs when a neonate is birthed or delivered prior to the completion of the 37th week of pregnancy. It s the leading cause of morbidity and the second leading

More information

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Acute and Maintenance Tocolysis Page 1 of 14 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Acute and Maintenance Tocolysis Professional Institutional Original

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atosiban 6.75 mg/0.9 ml solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ampoule (0.9 ml solution) contains 6.75

More information

Preterm Labour and Tocolysis

Preterm Labour and Tocolysis Title: CLINICAL GUIDELINES ID TAG Preterm Labour and Tocolysis Authors: Designation: Speciality / Division: Directorate: Dr L Bell, Dr K Price, Dr G McKeown, Mr D Sim Trainee, Trainee, CAH Consultant,

More information

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)

More information

Nifedipine Tocolysis Regime Policy

Nifedipine Tocolysis Regime Policy Document ID: MATY072 Version: 1.0 Facilitated by: Karen Wakelin, ACMM Issue Date: August 2010 Approved by: Maternity Quality Committee Review date: October 2017 Nifedipine Tocolysis Regime Policy Policy

More information

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Acute and Maintenance Tocolysis Page 1 of 17 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Acute and Maintenance Tocolysis Professional Institutional Original

More information

Adverse effects of tocolytic therapy

Adverse effects of tocolytic therapy BJOG: an International Journal of Obstetrics and Gynaecology March 2005, Vol. 112, Supplement 1, pp. 74 78 Adverse effects of tocolytic therapy Steve Caritis The rationale for using tocolytics in preterm

More information

Drugs used in obstetrics

Drugs used in obstetrics Drugs used in obstetrics Drugs used in obstetrics Drugs may be used to modify uterine contractions. These include oxytocic drugs used to stimulate uterine contractions both in induction of labour and to

More information

ATOSIBAN VERSUS NIFEDIPIN FOR THE MANAGEMENT OF PRETERM LABOR: A PROSPECTIVE STUDY

ATOSIBAN VERSUS NIFEDIPIN FOR THE MANAGEMENT OF PRETERM LABOR: A PROSPECTIVE STUDY AAMJ, VOL11, NO4, OCT 2013 SUPLL 2 ATOSIBAN VERSUS NIFEDIPIN FOR THE MANAGEMENT OF PRETERM LABOR: A PROSPECTIVE STUDY Tarek R. Abbas Department of Obstetrics and Gynecology, Al-Azhar Faculty of Medicine,

More information

TO COMPARE THE EFFECTIVENESS OF NIFEDIPINE AND GLYCERYL TRINITRATE PATCH IN PREVENTION OF PRETERM LABOUR ABSTRACT

TO COMPARE THE EFFECTIVENESS OF NIFEDIPINE AND GLYCERYL TRINITRATE PATCH IN PREVENTION OF PRETERM LABOUR ABSTRACT ORIGINAL ARTICLE TO COMPARE THE EFFECTIVENESS OF NIFEDIPINE AND GLYCERYL TRINITRATE PATCH IN PREVENTION OF PRETERM LABOUR 1-3 Department of Gynae & Obstetrics, Lady Reading Hospital, Peshawar - Pakistan.

More information

cardiovascular events when in use in these indications and the outcome of the review is summarised below.

cardiovascular events when in use in these indications and the outcome of the review is summarised below. Annex II Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation

More information

Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).

Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). VENTOL Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). Respiratory Solution Action Salbutamol is a short-acting, relatively selective beta2-adrenoceptor agonist.

More information

TOCOLYTIC DRUGS FOR WOMEN IN PRETERM LABOUR

TOCOLYTIC DRUGS FOR WOMEN IN PRETERM LABOUR Clinical Guideline No. 1(B) October 2002 (Replaces Guideline No.1 Beta-agonists and No.1 Ritodrine) TOCOLYTIC DRUGS FOR WOMEN IN PRETERM LBOUR 1. Purpose and scope Preterm birth is the most important single

More information

MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM

MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM Are Particular Anti-hypertensives More Effective or Harmful Than Others in Hypertension in Pregnancy? Existing data is inadequate Methyldopa and

More information

Efficacy and side effect of ritodrine and magnesium sulfate in threatened preterm labor

Efficacy and side effect of ritodrine and magnesium sulfate in threatened preterm labor Original Article Obstet Gynecol Sci 2018;61(1):63-70 https://doi.org/10.5468/ogs.2018.61.1.63 pissn 2287-8572 eissn 2287-8580 Efficacy and side effect of ritodrine and magnesium sulfate in threatened preterm

More information

A clinical study of feto-maternal outcome of. Isoxsuprine Hydrochloride in preterm labour

A clinical study of feto-maternal outcome of. Isoxsuprine Hydrochloride in preterm labour Original Research Article A clinical study of feto-maternal outcome of tocolytic agent nifedipine as compared to Isoxsuprine Hydrochloride in preterm labour Farzana Zahir 1*, Kalyan Kumar Nath 2, H H Choudhury

More information

CHAPTER 12 HYPERTENSION IN SPECIAL GROUPS HYPERTENSION IN PREGNANCY

CHAPTER 12 HYPERTENSION IN SPECIAL GROUPS HYPERTENSION IN PREGNANCY CHAPTER 12 HYPERTENSION IN SPECIAL GROUPS HYPERTENSION IN PREGNANCY v Mild preeclampsia is managed by close observation of the mother and fetus preferably in hospital. If the diastolic blood pressure remains

More information

Based on 2014 SOGC Guidelines

Based on 2014 SOGC Guidelines Based on 2014 SOGC Guidelines 22nd Edition 2015 1 ICH + gestational hypertension by far the biggest cause of direct maternal deaths New stats coming in 2013 OCR 22nd Edition 2015 2 Diastolic 90 mmhg is

More information

COMPARISON OF NEFIDIPINE WITH SOLBUTAMOL AS TOCOLYTIC AGENTS IN PRETERM LABOUR

COMPARISON OF NEFIDIPINE WITH SOLBUTAMOL AS TOCOLYTIC AGENTS IN PRETERM LABOUR E:/Biomedica Vol.23 Jul. Dec. 2007/Bio-10 (A) COMPARISON OF NEFIDIPINE WITH SOLBUTAMOL AS TOCOLYTIC AGENTS IN PRETERM LABOUR KIREN K. MALIK Department of Obstetrics and Gynaecology, Fatima Jinnah Medical

More information

The Treatment of Preterm Labor Using a Portable Subcutaneous Terbutaline Pump

The Treatment of Preterm Labor Using a Portable Subcutaneous Terbutaline Pump The Treatment of Preterm Labor Using a Portable Subcutaneous Terbutaline Pump D. JEAN SALA, RN, MSN, AND KENNETH J. MOISE, JR., MD The perinatal mortality rate related to preterm delivery has led researchers

More information

Durlaza. Durlaza (aspirin) Description

Durlaza. Durlaza (aspirin) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.13 Subject: Durlaza Page: 1 of 4 Last Review Date: September 15, 2016 Durlaza Description Durlaza

More information

Cyclo-oxygenase (COX) inhibitors for treating preterm labour (Review)

Cyclo-oxygenase (COX) inhibitors for treating preterm labour (Review) Cyclo-oxygenase (COX) inhibitors for treating preterm labour (Review) King JF, Flenady V, Cole S, Thornton S This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration

More information

Comparison of perinatal outcomes between long-term and short-term use of tocolytic agent: a historical cohort study in a single perinatal hospital

Comparison of perinatal outcomes between long-term and short-term use of tocolytic agent: a historical cohort study in a single perinatal hospital doi:10.1111/jog.13104 J. Obstet. Gynaecol. Res. Vol. 42, No. 12: 1680 1685, December 2016 Comparison of perinatal outcomes between long-term and short-term use of tocolytic agent: a historical cohort study

More information

Clinical features. Abnormal vasculogenesis and angiogenesis and releasing of antiangiogenic

Clinical features. Abnormal vasculogenesis and angiogenesis and releasing of antiangiogenic Clinical features Abnormal vasculogenesis and angiogenesis and releasing of antiangiogenic factors results in Vasospasm Endothelial dysfunction Etiology of various clinical signs and symptoms So, Preeclampsia

More information

You admitted a previously healthy nullipara at 36 weeks gestation who presented with new-onset periorbital edema and is found to have blood pressure

You admitted a previously healthy nullipara at 36 weeks gestation who presented with new-onset periorbital edema and is found to have blood pressure Preeclampsia Case report You admitted a previously healthy nullipara at 36 weeks gestation who presented with new-onset periorbital edema and is found to have blood pressure readings of 150/100 to 155/105

More information

Original Article Clinical efficacy of atosiban treatment in late abortion and preterm labour of twin pregnancy

Original Article Clinical efficacy of atosiban treatment in late abortion and preterm labour of twin pregnancy Int J Clin Exp Med 2016;9(2):3946-3952 www.ijcem.com /ISSN:1940-5901/IJCEM0016466 Original Article Clinical efficacy of atosiban treatment in late abortion and preterm labour of twin pregnancy Ya-Juan

More information

COMPARISON BETWEEN NIFEDIPINE AND RITODRINE AS AN EFFECTIVE TOCOLYTIC AGENT FOR PRETERM LABOUR

COMPARISON BETWEEN NIFEDIPINE AND RITODRINE AS AN EFFECTIVE TOCOLYTIC AGENT FOR PRETERM LABOUR Original Article COMPARISON BETWEEN NIFEDIPINE AND RITODRINE AS AN EFFECTIVE TOCOLYTIC AGENT FOR PRETERM LABOUR Nadeem Shahzad, 1 Faiqa Saleem, 2 Muhammad Shahid, 3 Aisha Malik 4 Abstract Background: Preterm

More information

BRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION

BRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION BRICANYL INJECTION terbutaline sulfate PRODUCT INFORMATION NAME OF THE MEDICINE Terbutaline sulfate, 2-(tert-butylamino)-1-(3,5-dihydroxyphenyl) ethanol sulfate, a sympathomimetic bronchodilator with a

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 9 1. NAME OF THE MEDICINAL PRODUCT Magnesium sulfate-kalceks 500 mg/ml solution for injection, BP * 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution

More information

2. Name of the focal point in WHO submitting or supporting the application

2. Name of the focal point in WHO submitting or supporting the application NIFEDIPINE Application 1. Summary statement of the proposal for inclusion Nifedipine, a calcium channel blocker already available in WHO Model Formulary 2004, needs an indication for threatened preterm

More information

1st Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and Kapodistrian University of Athens, Athens, Greece.

1st Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and Kapodistrian University of Athens, Athens, Greece. HJOG An Obstetrics and Gynecology International Journal HJOG 2019, 18 (1), 21-25 Christos Kalantzis, Kalliopi Pappa 1st Department of Obstetrics and Gynecology, Alexandra Maternity Hospital, National and

More information

Mercy San Juan Medical Center. Preeclampsia and Other Hypertensive Disorders of Pregnancy

Mercy San Juan Medical Center. Preeclampsia and Other Hypertensive Disorders of Pregnancy SUBJECT: Preeclampsia and Other Hypertensive Disorders of Pregnancy DEPARTMENTS: FBC, Emergency Department PURPOSE: To outline the nursing management of inpatients who have preeclampsia or other hypertensive

More information

azilsartan medoxomil

azilsartan medoxomil azilsartan medoxomil edarbi 40mg Tablet 80mg Tablet ANTIHYPERTENSIVE Angiotensin II Receptor Antagonist FORMULATION: Each tablet contains 40mg Azilsartan medoxomil (as potassium) Each tablet contains 80mg

More information

Policy REVISED: 6/30/2016 3:30 PM. Applies To: ObGyn Responsible Department: ObGyn Revised: June 30, 2016

Policy REVISED: 6/30/2016 3:30 PM. Applies To: ObGyn Responsible Department: ObGyn Revised: June 30, 2016 Title: Antihypertensive Treatment for Severe Hypertension During Pregnancy Applies To: ObGyn Responsible Department: ObGyn Revised: June 30, 2016 Policy POLICY STATEMENT: Pregnant or postpartum patients

More information

Magnesium Sulphate - Management of Hypertensive Disorders of Pregnancy

Magnesium Sulphate - Management of Hypertensive Disorders of Pregnancy 1. Purpose Magnesium sulphate is the anticonvulsant of choice for pre-eclampsia prophylaxis and treatment. This clinical guideline outlines the indications, contraindications, administration and monitoring

More information

CONTRAINDICATIONS Hypersensitivity to any component of this product (4)

CONTRAINDICATIONS Hypersensitivity to any component of this product (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OMIDRIA safely and effectively. See full prescribing information for OMIDRIA. OMIDRIA (phenylephrine

More information

Preterm birth is the leading cause of perinatal morbidity

Preterm birth is the leading cause of perinatal morbidity Nifedipine Compared With Atosiban for Treating Preterm Labor A Randomized Controlled Trial Raed Salim, MD, Gali Garmi, MD, Zohar Nachum, MD, Noah Zafran, MD, Shira Baram, MD, and Eliezer Shalev, MD OBJECTIVE:

More information

Angina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room

Angina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth University

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tractocile 6.75 mg/0.9 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of 0.9 ml solution contains

More information

50% Concentrated Injection

50% Concentrated Injection NAME OF THE MEDICINE. The molecular weight of the compound is 246.5 and the CAS registry number is 10034-99-8. The molecular formula is MgSO4, 7H2O. DESCRIPTION MAGNESIUM SULFATE HEPTAHYDRATE 50% CONCENTRATED

More information

Maternal Cardiac Disease Diagnosis and Management

Maternal Cardiac Disease Diagnosis and Management Maternal Cardiac Disease Diagnosis and Management Dr. Şevki ÇELEN ZTB Maternity and Teaching Hospital Department of Perinatology Heart diseases in pregnancy Today, 0.2-4% of all pregnancies are accompanied

More information

Medical Complications of Pregnancy

Medical Complications of Pregnancy Medical Complications of Pregnancy Systems Cardiovascular Pulmonary Endocrine Gastrointestinal Urologic Neurologic Cardiovascular System Physiologic anemia 3:1 increase of plasma volume:rbc mass Treat

More information

Angina Pectoris Dr. Shariq Syed

Angina Pectoris Dr. Shariq Syed Angina Pectoris Dr. Syed 1 What is Angina Pectoris (AP)? Commonly known as angina is chest pain often due to ischemia of the heart muscle, Because of obstruction or spasm of the coronary arteries 2 What

More information

DBL MAGNESIUM SULFATE CONCENTRATED INJECTION

DBL MAGNESIUM SULFATE CONCENTRATED INJECTION DBL MAGNESIUM SULFATE CONCENTRATED INJECTION NAME OF MEDICINE Magnesium Sulfate BP DESCRIPTION DBL Magnesium Sulfate Concentrated Injection is a clear, colourless, sterile solution. Each ampoule contains

More information

Acute Postpartum Pulmonary Edema: A Case Report

Acute Postpartum Pulmonary Edema: A Case Report Postpartum pulmonary edema 157 Acute Postpartum Pulmonary Edema: A Case Report Min-Po Ho 1, Wing-Keung Cheung 2, Kaung-Chau Tsai 1 Acute pulmonary edema after pregnancy is rare. Pulmonary emobolism, pneumonia,

More information

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic

More information

TERBUTALINE SULFATE INJECTION, USP

TERBUTALINE SULFATE INJECTION, USP 451001D/Revised: February 2011 TERBUTALINE SULFATE INJECTION, USP Rx only A sterile aqueous solution for subcutaneous injection. WARNING: PROLONGED TOCOLYSIS Terbutaline sulfate has not been approved and

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR: Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension

More information

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: 0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology

More information

TERBUTALINE SULFATE INJECTION, USP

TERBUTALINE SULFATE INJECTION, USP 451001C/Revised: March 2008 TERBUTALINE SULFATE INJECTION, USP Rx only A sterile aqueous solution for subcutaneous injection. DESCRIPTION: Terbutaline Sulfate Injection, USP, is a beta-adrenergic agonist

More information

LESSON ASSIGNMENT. After completing this lesson, you should be able to:

LESSON ASSIGNMENT. After completing this lesson, you should be able to: LESSON ASSIGNMENT LESSON 11 Oxytocics and Ergot Alkaloids. LESSON ASSIGNMENT Paragraphs 11-1 through 11-13. LESSON OBJECTIVES After completing this lesson, you should be able to: 11-1. Given a group of

More information

PHARMACEUTICAL INFORMATION AZILSARTAN

PHARMACEUTICAL INFORMATION AZILSARTAN AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-

More information

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval

More information

Intrapartum and Postpartum Management of the Diabetic Mother and Infant

Intrapartum and Postpartum Management of the Diabetic Mother and Infant Intrapartum and Postpartum Management of the Diabetic Mother and Infant Intrapartum Management Women with gestational diabetes who maintain normal glucose levels during pregnancy on diet and exercise therapy

More information

1.3 Sample Standard of Care from the Medical University of South Carolina

1.3 Sample Standard of Care from the Medical University of South Carolina 1.3 Sample Standard of Care from the Medical University of South Carolina Vitamin D Testing and Treatment Protocol MUSC Department of Ob-Gyn, Maternal-Fetal Medicine Division BACKGROUND: A rapidly evolving

More information

Ventolin Injection 500 micrograms (0.5mg), salbutamol, as sulphate, in 1ml (500 micrograms/ml).

Ventolin Injection 500 micrograms (0.5mg), salbutamol, as sulphate, in 1ml (500 micrograms/ml). Ventolin parenteral preparations Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION Ventolin Injection 500 micrograms (0.5mg), salbutamol, as sulphate, in 1ml (500 micrograms/ml). Ventolin Solution for

More information

Exam KEY. NROSCI/BIOSC 1070 and MSNBIO 2070 Exam # 2 October 23, 2015 Total POINTS: % of grade in class

Exam KEY. NROSCI/BIOSC 1070 and MSNBIO 2070 Exam # 2 October 23, 2015 Total POINTS: % of grade in class NROSCI/BIOSC 1070 and MSNBIO 2070 Exam # 2 October 23, 2015 Total POINTS: 100 20% of grade in class 1) Arterial and venous blood samples are taken, and other physiological measures are obtained, from a

More information

number Done by Corrected by Doctor

number Done by Corrected by Doctor number 9 Done by Nazek Hyasat Corrected by Bahaa Najjar & mohammed AL-shrouf Doctor Alia Shatnawi HOW DO DRUGS WORK??? You know that receptors are targeted by drugs, the question now is how do these drugs

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Actinobacteria, 413 Active treatment, survival rate and, 294 296 Air displacement plethysmography, 397 Airway obstruction, 309 310 Aluminum

More information

PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES

PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES Brand or Product Name [Product name] Suppositories mg Name and Strength of Active Substance(s) Eg Paracetamol 500mg Paracetamol 250mg Paracetamol 125mg

More information

Atosiban versus usual care for the management of preterm labor

Atosiban versus usual care for the management of preterm labor J. Perinat. Med. 35 (2007) 305 33 Copyright by Walter de Gruyter Berlin New York. DOI 0.55/JPM.2007.078 Atosiban versus usual care for the management of preterm labor Peter Husslein, *, Luis Cabero Roura

More information

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time

More information

Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review

Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review Bain et al. BMC Pregnancy and Childbirth 2013, 13:195 RESEARCH ARTICLE Open Access Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes:

More information

Prof dr Aleksandar Raskovic DIRECT VASODILATORS

Prof dr Aleksandar Raskovic DIRECT VASODILATORS Prof dr Aleksandar Raskovic DIRECT VASODILATORS Direct vasodilators Minoxidil (one of the most powerful peripheral arterial dilators) Opening of KATP channels, efflux of K, lose of Ca and smooth muscle

More information

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

P-RMS: IE/H/PSUR/0014/002

P-RMS: IE/H/PSUR/0014/002 Core Safety Profile Active substance: Nitroglycerin Pharmaceutical form(s)/strength: Transdermal patch 25mg, 50mg, 75mg (corresponding to 5, 10 and 15mg per 24 hours respectively P-RMS: IE/H/PSUR/0014/002

More information

Objectives. Medical Complications of Pregnancy. Potential Conflicts: None. Common Complicating Medical Conditions that Precede Pregnancy

Objectives. Medical Complications of Pregnancy. Potential Conflicts: None. Common Complicating Medical Conditions that Precede Pregnancy Medical Complications of Potential Conflicts: None Ellen W. Seely, M.D. Director of Clinical Research Endocrine-Hypertension Division Brigham and Women s Hospital Professor of Medicine Harvard Medical

More information

Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow

Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist

More information

Tocolytics for preterm premature rupture of membranes (Review)

Tocolytics for preterm premature rupture of membranes (Review) (Review) Mackeen AD, Seibel-Seamon J, Grimes-Dennis J, Baxter JK, Berghella V This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane

More information

Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults

Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed

More information

Vishwanath Pattan Endocrinology Wyoming Medical Center

Vishwanath Pattan Endocrinology Wyoming Medical Center Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected

More information

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,

More information

Facts About BELBUCA (buprenorphine) Buccal Film

Facts About BELBUCA (buprenorphine) Buccal Film Facts About BELBUCA (buprenorphine) Buccal Film Indication BELBUCA is a recent FDA-approved medication for the treatment of chronic pain severe enough to require daily, around-the-clock, long-term opioid

More information

Update on mangement of patent ductus arteriosus in preterm infants. Dr. Trinh Thi Thu Ha

Update on mangement of patent ductus arteriosus in preterm infants. Dr. Trinh Thi Thu Ha Update on mangement of patent ductus arteriosus in preterm infants Dr. Trinh Thi Thu Ha Outline 1. Overview of PDA 2. Timing of screening PDA? 3. When to treat PDA? Timing of ductal closure Prenatal

More information

Management of IUGR Prof. Dr. Acar KOÇ

Management of IUGR Prof. Dr. Acar KOÇ Management of IUGR Prof. Dr. Acar KOÇ Ankara University School of Medicine Department of OB&GYN Department of Perinatology Definition and Diagnosis: SGA IUGR EFW: < 10th percentile EFW: < 10th percentile

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Magnesium Trisilicate Mixture B.P. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Magnesium Trisilicate B.P. 250 mg/5 ml Light Magnesium

More information

P-RMS: LT/H/PSUR/0004/001

P-RMS: LT/H/PSUR/0004/001 Core Safety Profile Active substance: Dalteparine Pharmaceutical form(s)/strength: Solution for injection, 2500 I.U./0.2ml, 2500 I.U./ml, 5000 I.U./0.2ml, 7500 I.U./0.3ml, 7500 I.U./0.75ml, 10000 I.U./0.4ml,

More information

Active ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg

Active ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.

More information

Amiodarone Prescribing and Monitoring: Back to the Future

Amiodarone Prescribing and Monitoring: Back to the Future Amiodarone Prescribing and Monitoring: Back to the Future Subha L. Varahan, MD, FHRS, CCDS Electrophysiologist Oklahoma Heart Hospital Oklahoma City, OK Friday, February, 8 th, 2019 Iodinated benzofuran

More information

Stroke in Pregnancy. Stroke in Pregnancy 6/23/13

Stroke in Pregnancy. Stroke in Pregnancy 6/23/13 G5#$#Preven*ng#Maternal#Morbidity#and#Mortality#Via# Expanded#Scope#of#Nursing#Prac*ce#As#First#Responder# in#hypertensive#crisis#of#preeclampsia# The$presenter$reports$no$relevant,$influencing$financial$rela5onships.$

More information

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets PRODUCT INFORMATION Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets Product description Sudafed* Sinus + Anti-inflammatory Pain Relief caplets contain pseudoephedrine hydrochloride 30 mg and ibuprofen

More information

Hypoglycemia. Objectives. Glucose Metabolism

Hypoglycemia. Objectives. Glucose Metabolism Hypoglycemia Instructor: Janet Mendis, MSN, RNC-NIC, CNS Outline: Janet Mendis, MSN, RNC-NIC, CNS Summer Morgan, MSN, RNC-NIC, CPNP UC San Diego Health System Objectives State the blood glucose level at

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

numbe r Done by Corrected Docto Alia Shatnawi

numbe r Done by Corrected Docto Alia Shatnawi numbe r 9 Done by Nazek Hyasat Corrected Bahaa Najjar & mohammed AL-shrouf Docto Alia Shatnawi HOW DO DRUGS WORK??? You know that receptor targets by the drugs, the question now how these drugs work on

More information

Pain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia

Pain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans 2. Pain

More information

CONTRAINDICATIONS None (4)

CONTRAINDICATIONS None (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VAZCULEP safely and effectively. See full prescribing information for VAZCULEP. VAZCULEP (phenylephrine

More information

MAGNESIUM SULFATE IN WATER FOR INJECTION

MAGNESIUM SULFATE IN WATER FOR INJECTION MAGNESIUM SULFATE IN WATER FOR INJECTION Flexible Plastic Container For Intravenous Use Only Rx only DESCRIPTION Magnesium Sulfate in Water for Injection is a sterile, nonpyrogenic solution of magnesium

More information

Amlodipine plus Lisinopril Tablets AMLOPRES-L

Amlodipine plus Lisinopril Tablets AMLOPRES-L Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)

More information

PRODUCT INFORMATION VENTOLIN OBSTETRIC INJECTION FOR INTRAVENOUS INFUSION ONLY FOR OBSTETRIC USE ONLY - DILUTE BEFORE USE

PRODUCT INFORMATION VENTOLIN OBSTETRIC INJECTION FOR INTRAVENOUS INFUSION ONLY FOR OBSTETRIC USE ONLY - DILUTE BEFORE USE PRODUCT INFORMATION VENTOLIN OBSTETRIC INJECTION FOR INTRAVENOUS INFUSION ONLY FOR OBSTETRIC USE ONLY - DILUTE BEFORE USE DESCRIPTION: Ventolin Obstetric Injection contains salbutamol sulfate. Salbutamol

More information

Valve Disease in the Pregnant Patient

Valve Disease in the Pregnant Patient Valve Disease in the Pregnant Patient Julie B. Damp, MD December 6, 2012 VanderbiltHeart.com If single, do not allow marriage. If fertile, do not allow pregnancy. If pregnant, do not allow delivery. If

More information

Chapter 55. Changes in the Airway With COPD. Manifestations of Severe COPD. Drugs Used to Treat Obstructive Pulmonary Disorders

Chapter 55. Changes in the Airway With COPD. Manifestations of Severe COPD. Drugs Used to Treat Obstructive Pulmonary Disorders Chapter 55 Drugs Used to Treat Obstructive Pulmonary Disorders Changes in the Airway With COPD Manifestations of Severe COPD Air is trapped in the lower respiratory tract The alveoli degenerate and fuse

More information

Clinical practice evaluation of atosiban in preterm labour management in six European countries

Clinical practice evaluation of atosiban in preterm labour management in six European countries DOI: 10.1111/j.1471-0528.2006.01134.x www.blackwellpublishing.com/bjog Original article Clinical practice evaluation of atosiban in preterm labour management in six European countries P Husslein, a LC

More information

Pain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia

Pain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans. 1 Pain

More information

Objectives: This presentation will help you to:

Objectives: This presentation will help you to: emergency Drugs Objectives: This presentation will help you to: Five rights for medication administration Recognize different cardiac arrhythmias and determine the common drugs used for each one List the

More information